



## VENTOLIN™ RESPIRATOR SOLUTION

Salbutamol

### QUALITATIVE AND QUANTITATIVE COMPOSITION

VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml and 20 ml bottles.

### PHARMACEUTICAL FORM

Nebuliser solution.

### CLINICAL PARTICULARS

#### Indications

Salbutamol is a selective beta<sub>2</sub> adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. It provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. For patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger.

Bronchodilators should not be the only or main treatment in patients with persistent asthma. In patients with persistent asthma unresponsive to VENTOLIN, treatment with inhaled corticosteroids is recommended to achieve and maintain control. Failing to respond to treatment with VENTOLIN may signal a need for urgent medical advice or treatment.

VENTOLIN Respirator Solution is indicated for the routine management of chronic bronchospasm (unresponsive to conventional therapy) and treatment of acute severe asthma (status asthmaticus).

#### Dosage and Administration

VENTOLIN has a duration of action of 4 to 6 hours in most patients.

VENTOLIN Respirator Solution is to be used with a respirator or nebuliser, only under the direction of a physician.

The solution must not be injected, or swallowed.

Increasing use of beta<sub>2</sub> agonists may be a sign of worsening asthma. Under these conditions a reassessment of the patient's therapy plan may be required and concomitant glucocorticosteroid therapy should be considered.

Delivery of the aerosol may be by facemask, 'T' piece or via an endotracheal tube. Intermittent positive pressure ventilation may be used but is rarely necessary. When there is a risk of anoxia through hypoventilation, oxygen should be added to the inspired air.

As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.

As many nebulisers operate on a continuous flow basis, it is likely that nebulised drug will be released in the local environment. VENTOLIN Respirator Solution should therefore be administered in a well-ventilated room, particularly in hospitals when several patients may be using nebulisers in the same space at the same time.

#### 1. By intermittent administration

Intermittent treatment may be repeated 4 times daily.

##### • Adults

VENTOLIN Respirator Solution 0.5 to 1.0ml (2.5 to 5.0 milligrams of salbutamol) should be diluted to a final volume of 2.0 or 2.5ml using sterile normal saline as a diluent. The resulting solution is inhaled from a suitably driven nebuliser until aerosol generation ceases. Using a correctly matched nebuliser and driving source this should take about 10 minutes.

VENTOLIN Respirator Solution may be used undiluted for intermittent administration. For this, 2.0ml of VENTOLIN Respirator Solution (10.0 milligrams salbutamol) is placed in the nebuliser and the patient allowed to inhale the nebulised solution until bronchodilatation is achieved.

This usually takes 3 to 5 minutes.

Some adult patients may require higher doses of salbutamol, up to 10 milligrams, in which case nebulisation of the undiluted solution may continue until aerosol generation ceases.

##### • Children

The same mode of administration for intermittent administration is also applicable to children. The usual dosage for children under the age of 12 years is 0.5ml (2.5 milligrams salbutamol) diluted to 2.0 or 2.5ml using sterile normal saline as diluent. Some children may however require higher doses of salbutamol up to 5.0 milligrams.

Clinical efficacy of nebulised VENTOLIN in infants under 18 months is uncertain. As transient hypoxaemia may occur, supplemental oxygen therapy should be considered.

#### 2. By continuous administration

VENTOLIN Respirator Solution is diluted using sterile normal saline to contain 50-100 µg of salbutamol per ml, (1 to 2ml solution made up to 100ml with diluent). The diluted solution is administered as an aerosol by a suitably driven nebuliser. The usual rate of administration is 1 to 2 milligrams per hour.

#### Contraindications

VENTOLIN Respirator Solution is contraindicated in patients with a history of hypersensitivity to any of its components.

Non-i.v. formulations of VENTOLIN must not be used to arrest uncomplicated premature labour or threatened abortion.

#### Warnings and Precautions


The management of asthma should normally follow a stepwise programme, and patient response should be monitored clinically and by lung function tests.

Increasing use of short-acting inhaled beta<sub>2</sub> agonists to control symptoms indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed. Sudden and progressive deterioration in asthma control is potentially life threatening and consideration should be given to starting or increasing corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.

VENTOLIN Respirator solution must only be used by inhalation, to be breathed in through the mouth, and must not be injected or swallowed.

Patients receiving treatment at home with VENTOLIN Respirator Solution must be warned that if either the usual relief is diminished or the usual duration of action reduced, they should not increase the dose or its frequency of administration, but should seek medical advice.

VENTOLIN Respirator Solution should be used with caution in patients known to have received large doses of other sympathomimetic drugs.



VENTOLIN should be administered cautiously to patients with thyrotoxicosis.

A small number of cases of acute angle closure glaucoma have been reported in patients treated with a combination of nebulised VENTOLIN and ipratropium bromide. A combination of nebulised VENTOLIN with nebulised anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.

Potentially serious hypokalaemia may result from beta<sub>2</sub> agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.

As with other inhalation therapy, paradoxical bronchospasm may occur, resulting in an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator, if immediately available. VENTOLIN Respirator Solution should be discontinued, and if necessary a different fast-acting bronchodilator instituted for ongoing use.

In common with other β-adrenoceptor agonists, VENTOLIN can induce reversible metabolic changes, for example increased blood sugar levels. The diabetic patient may be unable to compensate for this and the development of ketacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect.

Lactic acidosis has been reported very rarely in association with high therapeutic doses of intravenous and nebulised short-acting beta-agonist therapy, mainly in patients being treated for an acute asthma exacerbation (see Adverse Reaction section). Increase in lactate levels may lead to dyspnoea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment. It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting.

#### Interactions

VENTOLIN and non-selective beta-blocking drugs, such as propranolol, should not usually be prescribed together.

VENTOLIN is not contraindicated in patients under treatment with monoamine oxidase inhibitors.

#### Pregnancy and Lactation

##### Fertility

There is no information on the effects of salbutamol on human fertility. There were no adverse effects on fertility in animals (see Pre-clinical Safety Data).

1000000127395

<b>GlaxoSmithKline</b>		<b>RSC A/W</b>
<b>Artwork Information</b>		<b>Version:</b>
<b>Panel</b>		<b>1</b>
<b>Item Number:</b> 1000000127395		
<b>Manufacturing Site:</b> GSK-GBR-Barnard Castle-UKBAR		
<b>Market or Pack Owner:</b> *Multi-Market Central-GEXP		
<b>Market Trade Name:</b> Ventolin		
<b>No. of Colours: 1</b> (does NOT include Varnish, if applicable)		
<b>List Colours:</b> (include sample in fields provided below; e.g. spot / spot-CMYK equivalent)		
<b>K</b>		
<b>Technical Reference No(s):</b> JMF165 (do NOT include the technical reference doc[s] version no[s].)		
<p><b>Artwork copyright is the property of the GlaxoSmithKline Group of Companies</b></p> <p>All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.</p> <p>The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.</p> <p>The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.</p>		
<b>ATTENTION • ATTENTION</b>		
<p><b>To Ensure Accurate PDF Viewing and Printing:</b></p> <p><b>FOR SCREEN VIEWING:</b> Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). <b>Overprint Preview</b> must be activated for accurate on screen viewing.</p> <p><b>FOR PRINTING:</b> Use only Acrobat Professional version 5 or higher. <b>"Apply Overprint Preview"</b> or <b>"Simulate Overprinting"</b> must be activated in the print settings for printing accurate hard copies.</p>		

180 mm Measuring Bar

AIP\_VERT\_MAD\_INDD - APR\_2010 Version 2

If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management system.

Front  
Page 1 of 2

## IMPORTANT

**GSK Market is responsible for this product, its design and content.**

**Ensure the artwork is thoroughly checked, all the text proof-read and approved.**

**RSC GSK is responsible for site technical requirements and pre-press suitability.**

**GSK Market is responsible to advise RSC in case changes required impact the followings:**

**Formulation  
Tablet embossing  
Storage conditions  
Shelf Life**

### TEXT SIZE CONTAINED IN THIS ARTWORK

Body text size: 7pt

Leading: 7pt

Horizontal Scale: 90%

Smallest text size: 7pt

Microtext: N

**Pregnancy**

Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus. During world-wide marketing experience, rare cases of various congenital anomalies, including cleft palate and limb defects have been reported in the offspring of patients being treated with salbutamol. Some of the mothers were taking multiple medications during their pregnancies. As no consistent pattern of defects can be discerned, and baseline rate for congenital anomalies is 2-3%, a relationship with salbutamol use cannot be established.

**Lactation**

As salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.

**Effects on Ability to Drive and Use Machines**

None reported.

**Adverse Reactions**

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000) including isolated reports. Very common and common events were generally determined from clinical trial data. Rare and very rare events were generally determined from spontaneous data.

**Immune system disorders**

Very rare: Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse

**Metabolism and nutrition disorders**

Rare: Hypokalaemia  
Potentially serious hypokalaemia may result from beta<sub>2</sub> agonist therapy.  
Very rare: Lactic acidosis

Lactic acidosis has been reported very rarely in patients receiving intravenous and nebulised salbutamol therapy for the treatment of acute asthma exacerbation.

**Nervous system disorders**

Common: Tremor, headache  
Very rare: Hyperactivity

**Cardiac disorders**

Common: Tachycardia  
Uncommon: Palpitations  
Very rare: Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles

**Vascular disorders**

Rare: Peripheral vasodilatation

**Respiratory, thoracic and mediastinal disorders**

Very rare: Paradoxical bronchospasm

**Gastrointestinal disorders**

Uncommon: Mouth and throat irritation

**Musculoskeletal and connective tissue disorders**

Uncommon: Muscle cramps

**Overdose**

The most common signs and symptoms of overdose with VENTOLIN are transient beta agonist pharmacologically mediated events (see Warnings and Precautions and Adverse Reactions). Hypokalaemia may occur following overdosage with VENTOLIN. Serum potassium levels should be monitored. Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose. During continuous administration of VENTOLIN Respirator Solution, any signs of overdosage can usually be counteracted by withdrawal of the drug.

**PHARMACOLOGICAL PROPERTIES**

**Pharmacodynamics**

Salbutamol is a selective beta<sub>2</sub>-adrenoceptor agonist. At therapeutic doses it acts on the beta<sub>2</sub>-adrenoceptors of bronchial muscle providing short acting (4 to 6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction.

**Pharmacokinetics**

**Absorption**

After administration by the inhaled route, between 10 and 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation but is not metabolised by the lung.

**Distribution**

Salbutamol is bound to plasma proteins to the extent of 10%.

**Metabolism**

On reaching the systemic circulation, salbutamol becomes accessible to hepatic metabolism and is excreted, primarily in the urine, as unchanged drug and as the phenolic sulphate.

The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine.

**Elimination**

Salbutamol administered intravenously has a half-life of four to six hours and is cleared partly renally and partly by metabolism to the inactive 4'-O-sulphate (phenolic sulphate) which is also excreted primarily in the urine. The faeces are a minor route of excretion. The majority of a dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours.

**Pre-clinical Safety Data**

In common with other potent selective beta<sub>2</sub> receptor agonists, salbutamol has been shown to be teratogenic in mice when given subcutaneously. In a reproductive study, 9.3% of foetuses were found to have cleft palate, at 2.5 mg/kg, 4 times the maximum human oral dose. In rats, treatment at the levels of 0.5, 2.32, 10.75 and 50mg/kg/day orally throughout pregnancy resulted in no significant foetal abnormalities.

The only toxic effect was an increase in neonatal mortality at the highest dose level as the result of lack of maternal care. A reproductive study in rabbits revealed cranial malformations in 37% of foetuses at 50mg/kg/day, 78 times the maximum human oral dose.

In an oral fertility and general reproductive performance study in rats at doses of 2 and 50 mg/kg/day, with the exception of a reduction in number of weanlings surviving to day 21 post partum at 50 mg/kg/day, there were no adverse effects on fertility, embryofetal development, litter size, birth weight or growth rate.

**PHARMACEUTICAL PARTICULARS**

**List of Excipients**

Purified water.  
Benzalkonium chloride.  
Dilute sulphuric acid.

**Incompatibilities**

None reported.

**Shelf Life**

The expiry date is indicated on the packaging.

**Special Precautions for Storage**

VENTOLIN Respirator Solution should be stored at a temperature below 25 °C and protected from light. Once the bottle has been opened the contents should be discarded after one month.

**Nature and Contents of Container**

Salbutamol, as sulphate, is supplied as a 5mg/ml solution in bottles of 10 ml and 20 ml.

**Instructions for Use/Handling**

Dilution:

VENTOLIN Respirator Solution may be diluted with sterile normal saline. Any unused solution in the chamber of the nebuliser must be discarded.

Not all presentations are available in every country.

Manufactured by:

Glaxo Operations UK Limited\*  
Barnard Castle  
UK

\*Member of the GSK group of companies

VENTOLIN is a trade mark of the GSK group of companies

©2014 GSK group of companies. All rights reserved

Version number: GDS25/IP109

Date of issue: 14 April 2014

1000000127395

GlaxoSmithKline  
Artwork Information  
Panel

RSC A/W  
Version:  
**1**

Item Number:  
1000000127395

Manufacturing Site:  
GSK-GBR-Barnard Castle-UKBAR

Market or Pack Owner:  
\*Multi-Market Central-GEXP

Market Trade Name:  
Ventolin

No. of Colours: 1  
(does NOT include Varnish, if applicable)

List Colours:  
(include sample in fields provided below;  
e.g. spot / spot-CMYK equivalent)

K			

Technical Reference No(s).:  
JMF165  
(do NOT include the technical reference doc[s] version no[s].)

**Artwork copyright is the property of the GlaxoSmithKline Group of Companies**  
All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

**ATTENTION • ATTENTION**  
**To Ensure Accurate PDF Viewing and Printing:**  
**FOR SCREEN VIEWING:** Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). **Overprint Preview** must be activated for accurate on screen viewing.  
**FOR PRINTING:** Use only Acrobat Professional version 5 or higher. **"Apply Overprint Preview"** or **"Simulate Overprinting"** must be activated in the print settings for printing accurate hard copies.

**Back**  
**Page 2 of 2**

**IMPORTANT**  
GSK Market is responsible for this product, its design and content.  
Ensure the artwork is thoroughly checked, all the text proof-read and approved.  
RSC GSK is responsible for site technical requirements and pre-press suitability.  
GSK Market is responsible to advise RSC in case changes required impact the followings:  
**Formulation**  
**Tablet embossing**  
**Storage conditions**  
**Shelf Life**

<b>TEXT SIZE CONTAINED IN THIS ARTWORK</b>
Body text size: 7pt
Leading: 7pt
Horizontal Scale: 90%
Smallest text size: 7pt
Microtext: N

180 mm Measuring Bar  
If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management system.